|
|
|
|
Gliadel Wafer
A biodegradable wafer that is used to deliver the anticancer drug carmustine directly into a brain tumor site after the tumor has been removed by surgery. Also called polifeprosan 20 carmustine implant. (National Cancer Institute)
Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data ... Mar 8, 2005
Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ... Yahoo News (press release)
Guilford takes wider loss as portfolio expands Mar 2, 2005
Sales of Guilford's Gliadel wafer, used to treat brain cancer, rose 44 percent to $27.7 million from $8.5 million in 2003, which the company credits to the ... Baltimore Business Journal,
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
<**results**>
Guilford Pharmaceuticals Announces Pricing of 10000000 Share ... Jul 1, 2004
Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ... Yahoo News (press release) -
Public Comment Sought on Proposed Rule for Medicare Payment for ... Jun 9, 2004
Inpatient Prospective Payment Systems and Fiscal Year 2005 Rates, in which the agency refuses to adequately reimburse hospitals for Gliadel Wafer, a standard-of ... Yahoo News (press release) -
Guilford expects $42M from stock offering Jul 1, 2004
...preclinical product candidates. Guilford is best known for its Gliadel wafer, used to treat brain-cancer tumors. The company recently ... Baltimore Business Journal, MD -
Guilford Pharmaceuticals Expands Marketing and Distribution ... May 17, 2004
...to market, sell and distribute its proprietary brain cancer therapy, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) in Germany, France, Benelux ... Yahoo News (press release) - May 17, 2004
... to market, sell and distribute its proprietary brain cancer therapy, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) in Germany, France, Benelux ...
Guilford Files Shelf Registration StatementYahoo News (press release) - May 20, 2004
... Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) and AGGRASTAT® Injection (tirofiban ...
Business DigestBaltimore Sun
Guilford Files Shelf Registration Statement May 20, 2004
Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) and AGGRASTAT® Injection (tirofiban ... Yahoo News (press release) - May 20, 2004
... Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) and AGGRASTAT® Injection (tirofiban ...
Business DigestBaltimore Sun
Business Digest May 21, 2004
It has two commercialized products: the Gliadel wafer for the treatment of brain cancer, and the Aggrastat injection, a heart drug. ... Baltimore Sun
Guilford joins Nasdaq Biotech Index May 17, 2004
Guilford currently markets the Gliadel Wafer for the treatment of brain cancer, and Aggrastat Injection for the treatment of acute coronary syndrome. ... Baltimore Business Journal
Guilford Begins Phase III Program For Aquavan Injection In ... May 10, 2004
...compared to $3.5 million in the first quarter a year ago, substantially all of which was attributable to revenue from the sale of Gliadel Wafer for the ... BioWorld Online (subscription) - May 10, 2004
... compared to $3.5 million in the first quarter a year ago, substantially all of which was attributable to revenue from the sale of Gliadel Wafer for the ...
Guilford Pharmaceuticals to Join NASDAQ Biotech IndexYahoo News (press release) - May 17, 2004
... Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ...
Guilford Pharmaceuticals Reports 2004 First Quarter ResultsPR Newswire (press release) - May 10, 2004
... For additional information about GLIADEL Wafer, please visit http://www.guilfordpharm.com under Products / Marketed Products / GLIADEL; and for AGGRASTAT ...
Guilford's loss grows to $18 millionBaltimore Sun
Guilford Pharmaceuticals to Join NASDAQ Biotech Index May 17, 2004
Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ... Yahoo News (press release) - May 17, 2004
... Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ...
Guilford Pharmaceuticals Reports 2004 First Quarter ResultsPR Newswire (press release) - May 10, 2004
... For additional information about GLIADEL Wafer, please visit http://www.guilfordpharm.com under Products / Marketed Products / GLIADEL; and for AGGRASTAT ...
Guilford's loss grows to $18 millionBaltimore Sun
Guilford Pharmaceuticals Reports 2004 First Quarter Results May 10, 2004
For additional information about GLIADEL Wafer, please visit http://www.guilfordpharm.com under Products / Marketed Products / GLIADEL; and for AGGRASTAT ... PR Newswire (press release) - May 10, 2004
... For additional information about GLIADEL Wafer, please visit http://www.guilfordpharm.com under Products / Marketed Products / GLIADEL; and for AGGRASTAT ...
Guilford's loss grows to $18 millionBaltimore Sun
Guilford's loss grows to $18 million May 11, 2004
The firm right now markets two commercial products: the Gliadel Wafer for brain cancer, and the Aggrastat Injection, which treats heart-attack patients. ... Baltimore Sun
IN BRIEF May 10, 2004
The company said the rise in revenue was attributable to an increase in the sales of its Gliadel Wafer product and the acquisition of Aggrastat Injection ... Washington Post
Resources from the National Cancer Institute on Gliadel Wafer:
Cancer.gov - Newly Approved Cancer Treatments In 1996, the FDA approved GLIADEL Wafer as an adjunct to surgery for the treatment
of patients with recurrent glioblastoma multiforme (GBM) brain tumors. ...
Cancer.gov ...prior procarbazine; Prior polifeprosan 20 with carmustine implant
(Gliadel wafer) allowed; Prior radiosensitizers allowed; No other ...
Cancer.gov - Adult Brain Tumors (PDQ®): Treatment Surgery plus radiation therapy. BCNU-impregnated polymer (Gliadel wafer)
implanted during initial surgery. A randomized double-blinded ...
List of Approved Oncology Drugs with Approved Indications File Format: PDF/Adobe Acrobat - View as HTML ... colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred
carmustine with Polifepro- san 20 Implant Gliadel Wafer Chemo For use in ...
Cancer.gov - Newly Approved Cancer Treatments Newly Approved Cancer Treatments. Information from the US Food and Drug Administration
(FDA) about recently approved cancer treatments. Updated: 02/27/2004, ...
|
|
|
